Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABS) Gains from Sales and Divestitures (2023 - 2025)

SAB Biotherapeutics (SABS) has disclosed Gains from Sales and Divestitures for 3 consecutive years, with $16723.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Gains from Sales and Divestitures fell 26.36% year-over-year to $16723.0, compared with a TTM value of $16723.0 through Dec 2025, down 26.36%, and an annual FY2025 reading of $16723.0, down 26.36% over the prior year.
  • Gains from Sales and Divestitures was $16723.0 for Q4 2025 at SAB Biotherapeutics, up from $12544.0 in the prior quarter.
  • Across five years, Gains from Sales and Divestitures topped out at $106250.0 in Q3 2023 and bottomed at $4182.0 in Q2 2024.
  • Average Gains from Sales and Divestitures over 3 years is $27661.5, with a median of $12816.0 recorded in 2023.
  • The sharpest move saw Gains from Sales and Divestitures crashed 94.42% in 2024, then soared 100.0% in 2025.
  • Year by year, Gains from Sales and Divestitures stood at $12816.0 in 2023, then skyrocketed by 77.19% to $22709.0 in 2024, then dropped by 26.36% to $16723.0 in 2025.
  • Business Quant data shows Gains from Sales and Divestitures for SABS at $16723.0 in Q4 2025, $12544.0 in Q3 2025, and $8364.0 in Q2 2025.